Fig. 1

PI3-kinase mutations are prognostic in molecular astrocytomas (diffuse gliomas with ATRX and/or TP53 mutations). a Data from TCGA samples (test cohort). Histology and grade of samples presented are listed in Additional file 1: Table S11; b Data from two validation cohorts (combined) from astrocytomas [17] and glioblastomas [6]. In both figures, only samples with an IDH mutation and TP53 or ATRX were selected. In these molecular astrocytomas, PI3 kinase mutations are prognostic for overall survival. P values indicated are calculated using the Log-rank test. Number of samples analysed are N = 144 (PIK3 wt) and N = 13 (PIK3 mutant) for the TCGA cohort and N = 22 (PIK3 wt) and N = 12 (PIK3 mutant) for the validation cohort